MENGENAI PODCAST INI 🔗

Purata panjang audio:
6 minutes
Bahasa Inggeris
Amerika Syarikat
10 episod
sejak 10 Ogo 2017
episodic

EPISOD TERKINI 🔗

Dr Golfinopoulos meets with ecancertv at IBCD 2016 to discuss SPECTA: a screening platform that sought to encourage patients to participate in clinical trials. He describes how regulatory involvement in trial design and drug design could be streamlined, and the issue of reimbursement for person ...

CARI EPISOD LEPAS

Cari episod lepas bagi IBCD 2016.

EPISOD SEBELUMNYA

Dr Malik speaks with ecancertv at IBCD 2016 to discuss the work of the National Cancer Institute in recruiting patients to clinical trials when subtyping limits disease-wide enrollment. She describes how 'exceptional responders' can be referred to the NCI for genotyping, and schemes to match pa ...
Dr Beer speaks with ecancertv at IBCD 2016 about making use of genomic data in a clinically actionable setting. He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries. Dr Beer describes how unregulated access and ...
Dr Schneider speaks with ecancertv at IBCD 2016 about the regulatory checkpoints to be passed in the development of assays. He highlights the difference in reproducibility and robustness of research and clinical assays, the clinical utility of validated biomarkers, and how beginning assay devel ...
Dr Lacombe speaks with ecancertv at IBCD 2016 about the role of the conference in communicating advances in drug development. He describes the presentations given during a session he chaired at the conference, including the research of Dr Shakun Malik and Dr Vassilis Golfinopoulos. Considering ...
Prof van Dongen speaks with ecancertv at IBCD 2016 about gaining deeper insight into drug action and suitability with radiolabelling. He describes how the journey of radiolabelled ligands may steer drug development, aiming for biomarkers and accumulating in tumours with localised tissue damage ...
Dr Gerstung speaks with ecancertv at IBCD 2016 about genetic analysis of AML patients that has contributed to a predictive model for treatment risk and outcomes. He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk ...
Dr Lively joins ecancer at IBCD 2016 to discuss presentations from the conference session she chaired. She discusses the work of Dr Simon Dovedi in developing assays for immune therapy, of Dr Robert Kinders in reproducibility and relevance of assays for clinical trials. Dr Lively reflects on t ...
Dr Vietz speaks with ecancertv at IBCD 2016 about the regulatory requirements and quality controls necessary for genomic profiling. She describes her work in constructing consistent, up to date guidelines for genomic assays, and considers balancing cost of access against comprehensive genetic t ...
Dr Hewitt speaks with ecancertv at IBCD 2016 about development of assays for predictive biomarkers as a part of personalised therapy. The use of biomarkers he describes could help with the selection of the most effective treatment for patients, depending on gene expression within tumours, and i ...
Penafian: Podcast dan karya seni yang dibenamkan pada halaman ini adalah daripada ecancer.org, yang merupakan hak milik pemiliknya dan tidak bergabung dengan atau disokong oleh Listen Notes, Inc.